TARSONS · NSE
Tarsons Products Limited
₹306.1
-0.55% (-₹1.7)
Prev. close
₹307.8
Volume
1,33,321
Delivery %
30.9%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Tarsons Products Limited
Tarsons Products Limited manufactures and trades in scientific plastic labware products in India and internationally. The company offers bottles and carboys; boxes and racks; cell cell culture ware, centrifuge ware, clamps and stands, cryoware, desiccator, tubings and connectors, filtration, genomics and PCR consumables, laboratory equipment and utilities, liquid handling consumables and reusables, magnetic stirrer bar, pp storage plates, sampling aids, vials and tubes, and volumetric reusables. It also provides general lab ware products. Its products are used in molecular biology, cell culture, genomics, proteomics, and immunology. Tarsons Products Limited was incorporated in 1983 and is headquartered in Kolkata, India.
Details
Sector
Healthcare
Industry
Medical Instruments & Supplies
CEO
Mr. Sanjive Sehgal
Headquarters
Kolkata
Employees
1,108
Website
tarsons.comExchange
View on NSE ↗Key stats
Market cap
₹1,628.64 Cr
P/E ratio (TTM)
146.5
EPS (TTM)
₹2.09
Beta (1Y · daily vs NIFTY 50)
1.24
Beta (5Y · monthly vs NIFTY 50)
1.55
Shares float
1.05 Cr
EPS · quarter ended Jun 2026
₹-0.27
Financial Performance
01 · Financials
FY22 growth needs FY21 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹300.79 Cr | ₹281.36 Cr | ₹296.39 Cr | ₹392.41 Cr | ₹422.51 Cr | |
| EBITDA | — | ₹161.17 Cr | ₹141.62 Cr | ₹111.29 Cr | ₹126.69 Cr | ₹140.97 Cr |
| — | ₹100.66 Cr | ₹80.71 Cr | ₹42.64 Cr | ₹29.77 Cr | ₹14.32 Cr | |
| Diluted EPS | — | ₹19.46 | ₹15.17 | ₹8.01 | ₹5.6 | ₹2.69 |
Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense, Other income, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹295.95 Cr | ₹544.23 Cr | ₹725.68 Cr | ₹972.18 Cr | ₹1,080.04 Cr | ₹1,185.82 Cr | |
| ₹33.50 Cr | ₹21.67 Cr | ₹110.69 Cr | ₹269.02 Cr | ₹339.17 Cr | ₹392.96 Cr | |
| Stockholders' equity | ₹244.34 Cr | ₹489.83 Cr | ₹569.30 Cr | ₹612.86 Cr | ₹630.21 Cr | ₹634.69 Cr |
Fixed assets, CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹83.47 Cr | ₹75.60 Cr | ₹102.71 Cr | ₹114.24 Cr | ₹118.48 Cr | |
| Investing cash flow | — | ₹-137.95 Cr | ₹-178.55 Cr | ₹-284.95 Cr | ₹-145.49 Cr | ₹-130.37 Cr |
| — | ₹129.58 Cr | ₹84.56 Cr | ₹135.63 Cr | ₹38.95 Cr | ₹8.93 Cr | |
| Capital expenditure | — | ₹-131.97 Cr | ₹-189.97 Cr | ₹-184.33 Cr | ₹-151.71 Cr | ₹-125.58 Cr |
| End cash position | ₹2.33 Cr | ₹77.44 Cr | ₹59.06 Cr | ₹17.11 Cr | ₹25.13 Cr | ₹23.19 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Nov 21–Dec 21(2Q) | Mar 22–Sep 25(15Q) | Dec 25–Jun 26(3Q) |
|---|---|---|---|
| Promoter | 47.30% | 47.31% | 47.30% |
| Public | 52.70% | 52.69% | 52.70% |
| Employee trusts | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Tarsons Products Limited | ₹1,642.21 Cr | ₹306.1 | 147.7 | 2.59 | 2.3% | 0.62 | +7.7% | -2.3% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Show all 13
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.